Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2011 1
2012 1
2013 1
2014 2
2015 1
2017 2
2018 2
2020 2
2021 4
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, Wu Y, Rajamanickam V, Bernard B, Hilgart-Martiszus I, Fountain CB, Morris G, Iwamoto N, Shimada T, Chang S, Traber PG, Zomer E, Horton JR, Shlevin H, Redmond WL. Curti BD, et al. Among authors: rolig as. J Immunother Cancer. 2021 Apr;9(4):e002371. doi: 10.1136/jitc-2021-002371. J Immunother Cancer. 2021. PMID: 33837055 Free PMC article. Clinical Trial.
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth.
Badeaux MD, Rolig AS, Agnello G, Enzler D, Kasiewicz MJ, Priddy L, Wiggins JF, Muir A, Sullivan MR, Van Cleef J, Daige C, Vander Heiden MG, Rajamanickam V, Wooldridge JE, Redmond WL, Rowlinson SW. Badeaux MD, et al. Among authors: rolig as. Cancer Immunol Res. 2021 Apr;9(4):415-429. doi: 10.1158/2326-6066.CIR-20-0317. Epub 2021 Jan 26. Cancer Immunol Res. 2021. PMID: 33500272
20 results